KALA BIO Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
KALA BIO has a total shareholder equity of $13.7M and total debt of $34.8M, which brings its debt-to-equity ratio to 253.8%. Its total assets and total liabilities are $61.6M and $47.9M respectively.
Anahtar bilgiler
253.8%
Borç/özkaynak oranı
US$34.82m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$54.20m |
| Eşitlik | US$13.72m |
| Toplam yükümlülükler | US$47.89m |
| Toplam varlıklar | US$61.61m |
Son finansal sağlık güncellemeleri
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: KALA's short term assets ($58.9M) exceed its short term liabilities ($19.2M).
Uzun Vadeli Yükümlülükler: KALA's short term assets ($58.9M) exceed its long term liabilities ($28.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: KALA has more cash than its total debt.
Borcun Azaltılması: KALA's debt to equity ratio has increased from 115.8% to 253.8% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: KALA has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: KALA has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 5.2% each year.